专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07723366B2 Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases 有权
标题翻译：唑类化合物作为用于治疗代谢疾病的丙二酰辅酶A脱羧酶抑制剂
公开(公告)号：US07723366B2
公开(公告)日：2010-05-25
申请号：US10468378
申请日：2002-02-19
申请人： Thomas Arrhenius , Jie Fei Cheng , Mark E. Wilson , Rossy Serafimov , Masahiro Nishimoto , David Mark Wallace , Sovouthy Tith , Steve Joel Brown , Charles Stanford Harmon , Gary D. Lopaschuk , Jason R. Dyck
发明人： Thomas Arrhenius , Jie Fei Cheng , Mark E. Wilson , Rossy Serafimov , Masahiro Nishimoto , David Mark Wallace , Sovouthy Tith , Steve Joel Brown , Charles Stanford Harmon , Gary D. Lopaschuk , Jason R. Dyck
IPC分类号： A61K31/425 , A61K31/445 , A61K31/44 , C07D277/72 , C07D277/00
CPC分类号： A61K31/423 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541
摘要： The present invention relates to methods of treatment of certain metabolic diseases, and to the use of compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, the invention relates to the use of compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the following formulae: (I) and (II) Wherein Y, C, R1, R2, R6, and R7 are defined herein.
摘要翻译：本发明涉及治疗某些代谢疾病的方法，以及使用化合物及其前药，和/或药学上可接受的盐，含有可用于治疗这些疾病的化合物的药物组合物。特别地，本发明涉及通过抑制丙二酰辅酶A脱羧酶（MCD）来治疗心血管疾病，糖尿病，癌症，酸中毒和肥胖的化合物和组合物的用途。这些化合物具有下式：（I）和（II）其中Y，C，R 1，R 2，R 6和R 7在本文中定义。

2. 发明授权

US07279477B2 Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators 有权
标题翻译：用作代谢调节剂的丙二酰辅酶A脱羧酶抑制剂
公开(公告)号：US07279477B2
公开(公告)日：2007-10-09
申请号：US10466926
申请日：2002-01-22
申请人： Thomas Arrhenius , Mi Chen , Jie Fei Cheng , Yujin Huang , Alex Michael Nadzan , Sovouthy Tith , David Mark Wallace , Bin Liu , Masahiro Nishimoto , Gary D. Lopaschuk , Jason R. Dyck
发明人： Thomas Arrhenius , Mi Chen , Jie Fei Cheng , Yujin Huang , Alex Michael Nadzan , Sovouthy Tith , David Mark Wallace , Bin Liu , Masahiro Nishimoto , Gary D. Lopaschuk , Jason R. Dyck
IPC分类号： A61K31/5375 , C07D265/30
CPC分类号： C07D231/06 , A61K31/16 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/42 , A61K31/44 , A61K31/5375 , C07C33/46 , C07C257/22 , C07C279/18 , C07C307/10 , C07C335/18 , C07D231/14 , C07D233/64 , C07D233/90 , C07D261/04 , C07D261/08 , C07D261/14 , C07D261/18 , C07D295/13 , C07D295/194 , C07D295/21 , C07D295/215 , C07D295/32 , C07D307/52 , C07D401/12 , C07F9/247 , C07F9/4021
摘要： The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
摘要翻译：本发明涉及新型化合物（I），其前药和药学上可接受的盐以及含有这样的化合物的药物组合物，其可用于治疗某些代谢疾病和通过抑制酶丙二酰辅酶A脱羧酶（丙二酰 - CoA脱羧酶，MCD）。特别地，本发明涉及通过抑制丙二酰辅酶A脱羧酶来预防，治疗和治疗心血管疾病，糖尿病，酸中毒，癌症和肥胖的化合物和组合物和方法。

3. 发明申请

US20080070869A1 Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators 审中-公开
标题翻译：用作代谢调节剂的丙二酰辅酶A脱羧酶抑制剂
公开(公告)号：US20080070869A1
公开(公告)日：2008-03-20
申请号：US11855984
申请日：2007-09-14
申请人： Thomas Arrhenius , Mi Chen , Jie Fei Cheng , Yujin Huang , Alex Nadzan , Sovouthy Tith , David Wallace , Bin Liu , Masahiro Nishimoto , Gary Lopaschuk , Jason Dyck
发明人： Thomas Arrhenius , Mi Chen , Jie Fei Cheng , Yujin Huang , Alex Nadzan , Sovouthy Tith , David Wallace , Bin Liu , Masahiro Nishimoto , Gary Lopaschuk , Jason Dyck
IPC分类号： A61K31/66 , A61K31/155 , A61K31/185 , A61P3/10 , A61P9/00 , A61P35/00 , A61P3/04 , A61K31/277
CPC分类号： C07D231/06 , A61K31/16 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/42 , A61K31/44 , A61K31/5375 , C07C33/46 , C07C257/22 , C07C279/18 , C07C307/10 , C07C335/18 , C07D231/14 , C07D233/64 , C07D233/90 , C07D261/04 , C07D261/08 , C07D261/14 , C07D261/18 , C07D295/13 , C07D295/194 , C07D295/21 , C07D295/215 , C07D295/32 , C07D307/52 , C07D401/12 , C07F9/247 , C07F9/4021
摘要： The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
摘要翻译：本发明涉及新型化合物（I），其前药和药学上可接受的盐以及含有这样的化合物的药物组合物，其可用于治疗某些代谢疾病和通过抑制酶丙二酰辅酶A脱羧酶（丙二酰 - CoA脱羧酶，MCD）。特别地，本发明涉及通过抑制丙二酰辅酶A脱羧酶来预防，治疗和治疗心血管疾病，糖尿病，酸中毒，癌症和肥胖的化合物和组合物和方法。

4. 发明申请

US20090030006A1 SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE 有权
标题翻译： SPIROKETAL衍生物及其作为糖尿病药物的用途
公开(公告)号：US20090030006A1
公开(公告)日：2009-01-29
申请号：US11815074
申请日：2006-01-27
申请人： Takamitsu Kobayashi , Tsutomu Sato , Masahiro Nishimoto
发明人： Takamitsu Kobayashi , Tsutomu Sato , Masahiro Nishimoto
IPC分类号： A61K31/352 , A61P3/10 , C07D493/10 , A61K31/381 , A61K31/4433 , A61K31/498 , A61K31/404 , A61K31/4155 , C07D495/20 , C07D491/20
CPC分类号： C07D311/96 , C07D491/153 , C07D493/10 , C07H19/01
摘要： The present invention provides a compound of Formula (I): wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(═O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6 alkoxy group or —NReRf; Ar1 represents an optionally substituted aromatic carbocyclic ring or an optionally mono-substituted aromatic heterocyclic ring; Q represents —(CH2)m-(L)p- or -(L)p-(CH2)m—; m represents an integer selected from 0 to 2, n represents an integer selected from 1 and 2, and p represents an integer selected from 0 and 1; L represents —O—, —S— or —NR5—; and A represents an optionally substituted aryl group or an optionally substituted heteroaryl group, a prodrug thereof and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical preparation or pharmaceutical composition comprising such a compound.
摘要翻译：本发明提供式（I）的化合物：其中R 1，R 2，R 3和R 4各自独立地选自氢原子，任选取代的C 1 -C 6烷基，任选取代的C 7 -C 14芳烷基和-C（ -O）Rx; Rx表示任选取代的C 1 -C 6烷基，任选取代的芳基，任选取代的杂芳基，任选取代的C 1 -C 6烷氧基或-NRrf; Ar 1表示任选取代的芳族碳环或任选单取代的芳族杂环; Q表示 - （CH 2）m - （L）p-或 - （L）p-（CH 2）m - ; m表示选自0至2的整数，n表示选自1和2的整数，p表示选自0和1的整数; L表示-O - ， - S-或-NR5-; A表示任选取代的芳基或任选取代的杂芳基，其前药及其药学上可接受的盐，以及包含这种化合物的药物制剂或药物组合物。

5. 发明授权

US06737417B2 Compounds with hydroxycarbonyl-halogenoalkyl side chain 失效
标题翻译：具有羟基羰基 - 卤代烷基侧链的化合物
公开(公告)号：US06737417B2
公开(公告)日：2004-05-18
申请号：US10149752
申请日：2002-06-13
申请人： JaeChon Jo , HeeAn Kwon , HyunSuk Lim , JaeYoung Choi , Kazumi Morikawa , Yoshitake Kanbe , Masahiro Nishimoto , MyungHwa Kim , Yoshikazu Nishimura
发明人： JaeChon Jo , HeeAn Kwon , HyunSuk Lim , JaeYoung Choi , Kazumi Morikawa , Yoshitake Kanbe , Masahiro Nishimoto , MyungHwa Kim , Yoshikazu Nishimura
IPC分类号： C07J100
CPC分类号： C07C59/64 , C07C51/38 , C07C59/54 , C07C59/56
摘要： The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1 represents a hydrogen atom, etc., R2 represents a C1-C7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.
摘要翻译：本发明提供由部分和化学键合到所述部分的基团组成的化合物，其中所述部分含有口服后具有低活性的化合物或其母体支架，并且所述基团具有以下通式（1）：其中R 1表示氢原子等，R2表示C1-C7卤代烷基等，m表示2〜14的整数，n表示2〜7的整数，或该化合物的对映异构体或其水合物或药学上可接受的盐其化合物或其对映异构体。上述化合物在药物用途中是有利的，因为通式（1）的基团允许化合物如抗雌激素的化合物在连接到化合物的母体支架上时在口服给药后显示出显着增加的活性。

6. 发明申请

US20120291866A1 METHOD OF MANUFACTURING THIN-FILM SOLAR CELL MODULE 审中-公开
标题翻译：制造薄膜太阳能电池模块的方法
公开(公告)号：US20120291866A1
公开(公告)日：2012-11-22
申请号：US13574125
申请日：2011-02-07
申请人： Masahiro Nishimoto , Toshiharu Uchimi
发明人： Masahiro Nishimoto , Toshiharu Uchimi
IPC分类号： H01L31/0224 , H01L31/18
CPC分类号： B32B37/1009 , B32B2305/34 , B32B2457/12 , H01L31/046 , H01L31/048 , H01L31/0481 , H01L31/0512 , Y02E10/50
摘要： A solar cell module is manufactured by resin-sealing a solar cell having a surface electrode to which a tab wire is connected, a tab wire is connected to the surface electrode and the solar cell is sealed with a sealing resin at a relative low temperature during the resin sealing step. For such purposes, a thin-film solar cell having a surface electrode to which a tab wire is connected is resin-sealed with a conductive adhesive film by using a decompression laminator, whereby the thin-film solar cell module is manufactured. A decompression laminator having a first chamber and a second chamber partitioned by a flexible sheet is used. Each chamber is capable of independent internal pressure adjustment. The second chamber includes a heating stage capable of heating. A resin mutually compatible with the thermoplastic resin constituting the conductive adhesive film is used as the sealing resin.
摘要翻译：太阳能电池模块通过树脂密封具有连接有突片线的表面电极的太阳能电池来制造，突片线连接到表面电极，并且太阳能电池在相对低的温度下用密封树脂密封树脂密封步骤。为了这样的目的，通过使用减压层压机，用导电性粘合剂膜将具有连接有突片线的表面电极的薄膜太阳能电池树脂密封，从而制造薄膜太阳能电池模块。使用具有由柔性片分隔开的第一室和第二室的减压层压机。每个室都能独立进行内部压力调节。第二室包括能够加热的加热台。使用与构成导电性粘合膜的热塑性树脂相溶的树脂作为密封树脂。

7. 发明授权

US08048897B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes 有权
标题翻译：环己烷衍生物，其前药及其盐，以及含有其的用于糖尿病的治疗剂
公开(公告)号：US08048897B2
公开(公告)日：2011-11-01
申请号：US11658400
申请日：2005-07-26
申请人： Hiroharu Matsuoka , Tsutomu Sato , Masahiro Nishimoto , Nobuo Shimma
发明人： Hiroharu Matsuoka , Tsutomu Sato , Masahiro Nishimoto , Nobuo Shimma
IPC分类号： A61K31/7028 , A61K31/403 , A61P3/10 , C07C63/00 , C07D209/04 , C07D213/62 , C07D231/14 , C07D307/79 , C07D317/48 , C07D333/34 , C07D333/56
CPC分类号： C07D333/32 , C07C35/14 , C07C35/48 , C07C43/23 , C07C43/253 , C07C69/94 , C07C217/58 , C07C235/46 , C07C255/54 , C07C317/22 , C07C323/18 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2601/16 , C07D209/12 , C07D213/64 , C07D231/12 , C07D307/80 , C07D317/54 , C07D333/56 , C07H15/203 , C07H17/00 , C07H17/02
摘要： A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH2—, or —NH—; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.
摘要翻译：具有降低血糖水平并且具有药物所需的优选性能的持久性药物活性，代谢稳定性和安全性的环己烷衍生物; 以及用于预防或治疗高血糖疾病（例如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病）），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：其中A是-O-，-CH2-或-NH-; n是选自0和1之间的整数; R6和R7各自独立地是氢或C1- 6烷基; m是选自1-3中的整数; Q选自下式Q1至Q5; Ar1是任选取代的亚芳基或任选取代的亚杂芳基，条件是杂亚芳基可以键合到芳族碳环或芳族杂环以形成稠合环; Ar 2是任选取代的芳基或任选取代的杂芳基），化合物的前药或其药学上可接受的盐。还提供含有化合物的药物，药物组合物等。

8. 发明授权

US07767651B2 Spiroketal derivatives and use thereof as diabetic medicine 有权
标题翻译：螺缩酮衍生物及其作为糖尿病药物的用途
公开(公告)号：US07767651B2
公开(公告)日：2010-08-03
申请号：US11815074
申请日：2006-01-27
申请人： Takamitsu Kobayashi , Tsutomu Sato , Masahiro Nishimoto
发明人： Takamitsu Kobayashi , Tsutomu Sato , Masahiro Nishimoto
IPC分类号： A01N43/04 , C07H1/00 , C07H3/00 , C08B37/00
CPC分类号： C07D311/96 , C07D491/153 , C07D493/10 , C07H19/01
摘要： The present invention provides a compound of Formula (I): wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(═O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6 alkoxy group or —NReRf; Ar1 represents an optionally substituted aromatic carbocyclic ring or an optionally mono-substituted aromatic heterocyclic ring; Q represents —(CH2)m-(L)p- or -(L)p-(CH2)m—; m represents an integer selected from 0 to 2, n represents an integer selected from 1 and 2, and p represents an integer selected from 0 and 1; L represents —O—, —S— or —NR5—; and A represents an optionally substituted aryl group or an optionally substituted heteroaryl group, a prodrug thereof and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical preparation or pharmaceutical composition comprising such a compound.
摘要翻译：本发明提供式（I）的化合物：其中R 1，R 2，R 3和R 4各自独立地选自氢原子，任选取代的C 1 -C 6烷基，任选取代的C 7 -C 14芳烷基和-C（ ΟO）Rx; Rx表示任选取代的C 1 -C 6烷基，任选取代的芳基，任选取代的杂芳基，任选取代的C 1 -C 6烷氧基或-NRrf; Ar 1表示任选取代的芳族碳环或任选单取代的芳族杂环; Q表示 - （CH 2）m - （L）p-或 - （L）p-（CH 2）m - ; m表示选自0至2的整数，n表示选自1和2的整数，p表示选自0和1的整数; L表示-O - ， - S-或-NR5-; A表示任选取代的芳基或任选取代的杂芳基，其前药及其药学上可接受的盐，以及包含这种化合物的药物制剂或药物组合物。

9. 发明申请

US20140124034A1 SOLAR CELL MODULE AND SOLAR CELL MODULE MANUFACTURING METHOD 审中-公开
标题翻译：太阳能电池模块和太阳能电池模块制造方法
公开(公告)号：US20140124034A1
公开(公告)日：2014-05-08
申请号：US14127626
申请日：2012-06-27
申请人： Masahiro Nishimoto , Daichi Mori
发明人： Masahiro Nishimoto , Daichi Mori
IPC分类号： H01L31/02 , H01L31/18
CPC分类号： H01L31/0201 , H01L31/046 , H02S30/10 , H02S40/34 , Y02E10/50
摘要： Disclosed is a terminal box with improved tab wire connection strength with limited warping and breakage of a translucent insulation substrate. A solar cell module is provided with: a solar cell with a cathode and an anode positioned on one surface thereof; a pair of power extraction tab wires which are connected onto the cathode and anode of the solar cell with a conductive adhesive layer interposed therebetween; and a pair of terminal box tab wires which are disposed on one surface of the solar cell with an insulating adhesive layer interposed therebetween, one end thereof being positioned on the cathode and the anode and which connect a terminal box with the pair of power extraction tab wires. The power extraction tab wires on the cathode and the anode are connected to the one end of the terminal box tab wires with the conductive adhesive layer interposed therebetween.
摘要翻译：公开了一种接线盒，其具有改进的接头线连接强度，并且具有有限的翘曲和半透明绝缘基板的断裂。太阳能电池模块设置有：具有位于其一个表面上的阴极和阳极的太阳能电池; 一对功率提取标签线，其连接到太阳能电池的阴极和阳极上，导电粘合剂层插入其间; 以及配置在太阳能电池的一个表面上的绝缘粘合剂层的一对接线盒接头线，其一端位于阴极和阳极上，并将接线盒与一对电力提取接头连接电线阴极和阳极上的功率提取标签线与介于其间的导电粘合剂层连接到接线盒标签线的一端。

10. 发明授权

US08207134B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug 失效
标题翻译：稠环螺旋酮衍生物及其作为抗糖尿病药物的用途
公开(公告)号：US08207134B2
公开(公告)日：2012-06-26
申请号：US12375378
申请日：2007-07-27
申请人： Tsutomu Sato , Yoshihito Ohtake , Masahiro Nishimoto , Takashi Emura , Takamitsu Kobayashi , Marina Yamaguchi , Kyouko Takami
发明人： Tsutomu Sato , Yoshihito Ohtake , Masahiro Nishimoto , Takashi Emura , Takamitsu Kobayashi , Marina Yamaguchi , Kyouko Takami
IPC分类号： A01N43/04 , A61K31/70 , C07H1/00 , C07H3/00 , C08B37/00
CPC分类号： C07H19/01
摘要： Provided are a compound represented by Formula (I): wherein R1, R2, R3, and R4 are each independently selected from a hydrogen atom, a C1-6 alkyl group which may be substituted, a C7-14 aralkyl group which may be substituted and —C(═O)Rx; n denotes an integer selected from 1 and 2; and ring Ar is selected from the groups represented by the following Formula (a) to (f). or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
摘要翻译：提供由式（I）表示的化合物：其中R 1，R 2，R 3和R 4各自独立地选自氢原子，可被取代的C 1-6烷基，可被取代的C 7-14芳烷基和-C（= O）Rx; n表示选自1和2的整数; 并且环Ar选自由下式（a）至（f）表示的基团。或其前药或其药学上可接受的盐，以及药物和含有这种化合物或其前药的药物组合物或其药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式